216 related articles for article (PubMed ID: 17914081)
21. Effects of Temozolomide and Radiotherapy on Brain Metastatic Tumor: A Systematic Review and Meta-Analysis.
Ma W; Li N; An Y; Zhou C; Bo C; Zhang G
World Neurosurg; 2016 Aug; 92():197-205. PubMed ID: 27072333
[TBL] [Abstract][Full Text] [Related]
22. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
Huncharek M; Caubet JF; McGarry R
Melanoma Res; 2001 Feb; 11(1):75-81. PubMed ID: 11254118
[TBL] [Abstract][Full Text] [Related]
23. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
Carvajal RD; Sosman JA; Quevedo JF; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski TF; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Lewis K; Doyle A; Ancell K; Panageas KS; Bluth M; Hedvat C; Erinjeri J; Ambrosini G; Marr B; Abramson DH; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK
JAMA; 2014 Jun; 311(23):2397-405. PubMed ID: 24938562
[TBL] [Abstract][Full Text] [Related]
24. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
Hwu WJ; Lis E; Menell JH; Panageas KS; Lamb LA; Merrell J; Williams LJ; Krown SE; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
Cancer; 2005 Jun; 103(12):2590-7. PubMed ID: 15861414
[TBL] [Abstract][Full Text] [Related]
25. Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
Ferrucci PF; Minchella I; Mosconi M; Gandini S; Verrecchia F; Cocorocchio E; Passoni C; Pari C; Testori A; Coco P; Munzone E
Melanoma Res; 2015 Jun; 25(3):239-45. PubMed ID: 25746039
[TBL] [Abstract][Full Text] [Related]
26. [Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities].
Koprowska K; Czyż M
Postepy Hig Med Dosw (Online); 2011 Nov; 65():734-51. PubMed ID: 22173438
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).
Krown SE; Niedzwiecki D; Hwu WJ; Hodgson L; Houghton AN; Haluska FG;
Cancer; 2006 Oct; 107(8):1883-90. PubMed ID: 16986123
[TBL] [Abstract][Full Text] [Related]
28. Radiochemotherapy for brain metastasis: how to define a role for temozolomide.
Weller M
Onkologie; 2007 Jul; 30(7):350-1. PubMed ID: 17596741
[No Abstract] [Full Text] [Related]
29. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Plummer ER; Middleton MR; Jones C; Olsen A; Hickson I; McHugh P; Margison GP; McGown G; Thorncroft M; Watson AJ; Boddy AV; Calvert AH; Harris AL; Newell DR; Curtin NJ
Clin Cancer Res; 2005 May; 11(9):3402-9. PubMed ID: 15867241
[TBL] [Abstract][Full Text] [Related]
30. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
Paul MJ; Summers Y; Calvert AH; Rustin G; Brampton MH; Thatcher N; Middleton MR
Melanoma Res; 2002 Apr; 12(2):175-8. PubMed ID: 11930115
[TBL] [Abstract][Full Text] [Related]
31. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.
Bafaloukos D; Tsoutsos D; Fountzilas G; Linardou H; Christodoulou C; Kalofonos HP; Briassoulis E; Panagiotou P; Hatzichristou H; Gogas H
Melanoma Res; 2004 Aug; 14(4):289-94. PubMed ID: 15305160
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
Hwu WJ; Panageas KS; Menell JH; Lamb LA; Aird S; Krown SE; Williams LJ; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
Cancer; 2006 Jun; 106(11):2445-51. PubMed ID: 16639739
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
Laber DA; Okeke RI; Arce-Lara C; Taft BS; Schonard CL; McMasters KM; Kloecker GH; Miller DM
J Cancer Res Clin Oncol; 2006 Sep; 132(9):611-6. PubMed ID: 16741726
[TBL] [Abstract][Full Text] [Related]
34. Temozolomide for recurrent high-grade glioma.
Macdonald DR
Semin Oncol; 2001 Aug; 28(4 Suppl 13):3-12. PubMed ID: 11550133
[TBL] [Abstract][Full Text] [Related]
35. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.
Hofmann M; Kiecker F; Wurm R; Schlenger L; Budach V; Sterry W; Trefzer U
J Neurooncol; 2006 Jan; 76(1):59-64. PubMed ID: 16132502
[TBL] [Abstract][Full Text] [Related]
36. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
Larkin JM; Hughes SA; Beirne DA; Patel PM; Gibbens IM; Bate SC; Thomas K; Eisen TG; Gore ME
Br J Cancer; 2007 Jan; 96(1):44-8. PubMed ID: 17146474
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Bael TE; Peterson BL; Gollob JA
Melanoma Res; 2008 Apr; 18(2):147-51. PubMed ID: 18337652
[TBL] [Abstract][Full Text] [Related]
38. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW
Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674
[TBL] [Abstract][Full Text] [Related]
39. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide.
Rinne ML; Wen PY
Oncology (Williston Park); 2015 Apr; 29(4):265, 275. PubMed ID: 25952491
[No Abstract] [Full Text] [Related]
40. Medical treatment of uveal melanoma.
Queirolo P; Acquati M
Tumori; 2007; 93(3):suppl 27-30. PubMed ID: 17679486
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
